1
|
Zaniboni A, Meriggi F, Alghisi A, Mutti S, Distefano L, Rizzi A, Bettini L, Simoncini E, Marpicati P, Montini E. Mitomycin-C and Lonidamine as Second-Line Therapy for Colorectal Cancer: A Phase II Study. TUMORI JOURNAL 2018; 81:435-7. [PMID: 8804471 DOI: 10.1177/030089169508100610] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aims and background Recent preclinical data have suggested that lonidamine may potentiate the activity of mitomycin C in human colon cancer cell lines LoVo and HT29. Study design A phase II study was carried out in 14 patients with advanced colorectal cancer pretreated with fluorouracil and folinic acid. Treatment consisted of lonidamine, 600 mg po, followed after 2 h by mitomycin, 20 mg/m2 by iv bolus, followed by lonidamine, 150 mg tid for 5 days; the cycle was repeated every 6 weeks. Results No objective response was seen. Three patients had stable disease; the median survival for the whole group was 4 months. Although hematologic toxicity was negligible, lonidamine-related side effects were moderate to severe in most patients and mainly represented by myalgia and gastric pain. Discussion Despite a sound preclinical rationale, this schedule of lonidamine and mitomycin C was ineffective and toxic in patients with advanced colorectal cancer. More experimental data about lonidamine are needed in order to design more effective regimens based on the combination of this interesting drug with other anticancer agents.
Collapse
Affiliation(s)
- A Zaniboni
- Servizio di Oncologia, Spedali Civili, Brescia, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Satta F, Konstantatou E, Nigita G, Tocchi A, Accordino M, Franchi F. Comparison between an Apparently Obsolete Protocol and an Updated Regimen in the Salvage Treatment of Advanced Colorectal Cancer. Clin Drug Investig 2000. [DOI: 10.2165/00044011-200020050-00010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
3
|
Murren JR, Rappa G, Cheng YC. Multifunctional modulators of drug resistance. Cancer Treat Res 1996; 87:381-408. [PMID: 8886462 DOI: 10.1007/978-1-4613-1267-3_16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Affiliation(s)
- J R Murren
- Yale Cancer Center, Yale University School of Medicine, Department of Medicine, New Haven, CT 06520, USA
| | | | | |
Collapse
|